Esperion Therapeutics Inc [ESPR] stock is trading at $0.86, up 7.75%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ESPR shares have gain 8.14% over the last week, with a monthly amount drifted -9.06%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Esperion Therapeutics Inc [NASDAQ: ESPR] stock has seen the most recent analyst activity on December 18, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $4. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on December 17, 2024, and set its price target to $8. On June 20, 2024, downgrade downgraded it’s rating to Underperform but maintained its price target of $2.50 on the stock. BofA Securities downgraded its rating to a Neutral. Northland Capital upgraded its rating to Market Perform for this stock on August 01, 2023. In a note dated June 15, 2023, BofA Securities upgraded an Buy rating on this stock and boosted its target price from $1.25 to $4.
Esperion Therapeutics Inc [ESPR] stock has fluctuated between $0.69 and $3.94 over the past year. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Esperion Therapeutics Inc [NASDAQ: ESPR] shares were valued at $0.86 at the most recent close of the market. An investor can expect a potential return of 830.23% based on the average ESPR price forecast.
Analyzing the ESPR fundamentals
Esperion Therapeutics Inc [NASDAQ:ESPR] reported sales of 259.57M for the trailing twelve months, which represents a drop of -52.81%. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -0.15%, Pretax Profit Margin comes in at -0.59%, and Net Profit Margin reading is -0.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is 0.4 and Total Capital is -0.75. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.7.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Esperion Therapeutics Inc’s Current Ratio is 1.18. As well, the Quick Ratio is 0.81, while the Cash Ratio is 0.42. Considering the valuation of this stock, the price to sales ratio is 0.66.
Transactions by insiders
Recent insider trading involved Warren Eric, Chief Commercial Officer, that happened on Apr 17 ’25 when 108.0 shares were sold. Chief Financial Officer, Halladay Benjamin completed a deal on Apr 17 ’25 to sell 8.0 shares. Meanwhile, Officer Halladay Benjamin bought 8.0 shares on Apr 17 ’25.
